Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/117722
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Vincent, F.B. | - |
dc.contributor.author | Kandane-Rathnayake, R. | - |
dc.contributor.author | Hoi, A.Y. | - |
dc.contributor.author | Slavin, L. | - |
dc.contributor.author | Godsell, J.D. | - |
dc.contributor.author | Kitching, A.R. | - |
dc.contributor.author | Harris, J. | - |
dc.contributor.author | Nelson, C.L. | - |
dc.contributor.author | Jenkins, A.J. | - |
dc.contributor.author | Chrysostomou, A. | - |
dc.contributor.author | Hibbs, M.L. | - |
dc.contributor.author | Kerr, P.G. | - |
dc.contributor.author | Rischmueller, M. | - |
dc.contributor.author | Mackay, F. | - |
dc.contributor.author | Morand, E.F. | - |
dc.date.issued | 2018 | - |
dc.identifier.citation | Lupus, 2018; 27(13):2029-2040 | - |
dc.identifier.issn | 0961-2033 | - |
dc.identifier.issn | 1477-0962 | - |
dc.identifier.uri | http://hdl.handle.net/2440/117722 | - |
dc.description.abstract | INTRODUCTION:We examined the clinical relevance of urinary concentrations of B-cell-activating factor of the tumour necrosis factor family (BAFF) and a proliferation-inducing ligand (APRIL) in systemic lupus erythematosus (SLE). METHODS:We quantified urinary BAFF (uBAFF) by enzyme-linked immunosorbent assay in 85 SLE, 28 primary Sjögren syndrome (pSS), 40 immunoglobulin A nephropathy (IgAN) patients and 36 healthy controls (HCs). Urinary APRIL (uAPRIL) and monocyte chemoattractant protein 1 (uMCP-1) were also quantified. Overall and renal SLE disease activity were assessed using the Systemic Lupus Erythematosus Disease Activity Index 2000. RESULTS:uBAFF was detected in 12% (10/85) of SLE patients, but was undetectable in HCs, IgAN and pSS patients. uBAFF was detectable in 28% (5/18) of SLE patients with active nephritis vs 5/67 (7%) of those without ( p = 0.03), and uBAFF was significantly higher in active renal patients ( p = 0.02) and more likely to be detected in patients with persistently active renal disease. In comparison, uAPRIL and uMCP-1 were detected in 32% (25/77) and 46% (22/48) of SLE patients, respectively. While no difference in proportion of samples with detectable uAPRIL was observed between SLE, HCs and IgAN patients, both uAPRIL and uMCP-1 were significantly detectable in higher proportions of patients with active renal disease. CONCLUSIONS:uBAFF was detectable in a small but a significant proportion of SLE patients but not in other groups tested, and was higher in SLE patients with active renal disease. | - |
dc.description.statementofresponsibility | F B Vincent, R Kandane-Rathnayake, A Y Hoi, L Slavin, J D Godsell, A R Kitching, J Harris, C L Nelson, A J Jenkins, A Chrysostomou, M L Hibbs, P G Kerr, M Rischmueller, F Mackay, E F Morand | - |
dc.language.iso | en | - |
dc.publisher | SAGE Publishing | - |
dc.rights | © The Author(s), 2018. Reprints and permissions: http://www.sagepub.co.uk/journalsPermissions.nav | - |
dc.source.uri | http://dx.doi.org/10.1177/0961203318804885 | - |
dc.subject | A proliferation-inducing ligand (APRIL); B-cell–activating factor from the tumour necrosis factor family (BAFF); biomarker; lupus nephritis (LN); monocyte chemoattractant protein 1 (MCP-1); systemic lupus erythematosus (SLE) | - |
dc.title | Urinary B-cell-activating factor of the tumour necrosis factor family (BAFF) in systemic lupus erythematosus | - |
dc.type | Journal article | - |
dc.identifier.doi | 10.1177/0961203318804885 | - |
pubs.publication-status | Published | - |
dc.identifier.orcid | Rischmueller, M. [0000-0001-5057-3286] | - |
Appears in Collections: | Aurora harvest 8 Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.